House Appropriators Tell FDA to Accelerate its IND Sign-Off
Congress wants faster entry into early-phase trials as drug development keeps shifting toward China and Australia.
Some important congressional news for the drug developers among us. As reported in Endpoints News, the House Appropriations Committee has directed the FDA to rework how it clears new clinical trials. It’s part of a wider effort in Washington to keep early drug development from moving offshore.
The instruction appears in the committee’s report accompanying the fiscal year 2027 Agriculture and FDA funding bill, which the House just passed by a vote of 213 to 210.
In the report, the committee directs the agency to revise its investigational new drug (IND) processes and data requirements for initial human trials to:
Streamline administrative requirements.
Reduce filing burdens.
Make them phase- and risk-appropriate.
The committee said it recognizes that many Phase 1 trials are better understood as a continuation of early proof-of-concept research than as part of a traditional commercial drug development program, language that points toward lighter requirements at the very start of testing.
The committee also encouraged the FDA to build a pilot modeled on Australia’s clinical trial notification system. Under that approach, lower-risk INDs would be reviewed by academic medical center institutional review boards, with agency or third-party support to supplement that expertise rather than a full FDA sign-off before a trial begins.
This lines up with the FDA’s own request
The direction from House appropriators tracks closely with what the agency asked for in its fiscal year 2027 budget. That request proposed an optional, risk-based “expedited IND” pathway for experimental drugs whose existing preclinical data can be confirmed without animal testing.
The proposal is now under review at the White House Office of Information and Regulatory Affairs.
Much of the early momentum is reported to have come from former FDA Commissioner Marty Makary, who pushed for institutional review board reform before stepping down. Speaking at the 2026 CMS Quality Conference in Baltimore alongside CMS Administrator Mehmet Oz and NIH Director Jay Bhattacharya, Makary said China starts about four times as many Phase 1 trials as the United States.
He put the average pre-IND timeline at roughly 380 days in the US against about 220 in China, and said China had announced plans to compress that to 60. He argued that a research system depending on a monthly volunteer committee of staff, the way IRB review often works, can’t keep that pace.
(Makary resigned on May 12 amid White House pressure following a dispute over flavored e-cigarette approvals. Kyle Diamantas, the agency’s top food official, is serving as acting commissioner while the administration looks for a permanent replacement, which leaves the future of these reforms partly in the hands of leadership that has not yet been named.)
Reform interest looks bipartisan
The appropriations directive is not the only push on early-phase trials.
Rep. Jake Auchincloss (D-MA) has advanced a bipartisan proposal that would expand the FDA’s role in clinical trials embedded in routine clinical care.
Sen. Bill Cassidy (R-LA) earlier released a report outlining IND-related problems at the agency as part of a broader argument for FDA modernization.
The money and what’s probably coming next
The underlying bill would give the FDA about $7.1 billion for fiscal 2027, roughly $200 million more than the current year and somewhat below the $7.2 billion the administration requested. It cleared the House 213 to 210, with five Republicans voting against and four Democrats voting in favor.
The Senate has not taken up its version. The Senate Appropriations Committee postponed its markup to a date it has not announced, so the IND language is not final and could change before any bill reaches the president.
For sponsors planning first-in-human work, we see three questions that are still open:
Whether the expedited IND pilot clears White House review
Whether the Senate keeps the House’s IND language
How a permanent commissioner approaches early-phase reform once one is in place.
None of that is settled yet, but the direction of travel in both the budget request and the appropriations report is hard to miss. We’ll keep you posted when there’s more to report.
Talk to us if you need IND submission or related regulatory support. We have a deep bench of experienced IND experts and routinely help with all dimensions of IND strategy, preparation, and submission.
Who is The FDA Group?
The FDA Group helps life science organizations rapidly access the industry's best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus on Quality Assurance, Regulatory Affairs, and Clinical Operations.
With thousands of resources worldwide, hundreds of whom are former FDA, we meet your precise resourcing needs through a fast, convenient talent selection process supported by a Total Quality Guarantee. Learn more and schedule a call with us to see if we’re a fit to help you access specialized professionals and execute your projects on time and on budget.